Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Impurities in Sugar Excipients Could Cause Drugs to Fail

By Leiden University | December 19, 2016

Sugar excipients, needed to stabilize medicines, can be unsafe for patients due to a recently discovered impurity by researcher Daniel Weinbuch, Ph.D., during studies at Leiden University in The Netherlands. “Therefore, the biopharmaceutical industry should consider new excipient quality criteria for safer drug development,” he says.

Modern Medicines Are Folded Like Origami

Biopharmaceuticals, the fastest growing class of therapeutics, are very successful in treating chronic and life-threatening diseases, such as multiple sclerosis, diabetes and cancers. The active substances are often very large proteins such as antibodies, which are about a thousand times larger than small molecules such as ibuprofen. These large molecules are often very fragile, because they need to be folded properly, almost like origami, to fulfill their function.

Damaged Proteins Can Be Harmful for the Patient

If such proteins are damaged during production, storage, shipment, or administration, they can unfold and aggregate. They form into particles that can even become large enough to be seen with the naked eye. The immune system in the body of the patient might attack these particles, especially those in the nanometer and micrometer size. This reaction, which is called unwanted immunogenicity, can cause life-threatening immunological side effects.

New Techniques Identify Harmful Particles

Particles in the nanometer and micrometer size are omnipresent and do not necessarily have to originate from the therapeutic protein itself. “It was very important to establish new techniques in order to understand where these particles come from and how dangerous they might be for the patient,” says Weinbuch, who did his Ph.D. research at the Leiden Academic Center for Drug Research (LACDR) in collaboration with Coriolis Pharma.

Weinbuch: “When we started our research project, there were very few analytical techniques available to measure and differentiate nanometer and micrometer particles.” Therefore, he evaluated new and emerging techniques during his Ph.D., such as resonant mass measurement and flow imaging microscopy.

Stabilizing Sugar Can Make Drugs Unsafe

Sugar excipients are commonly used for many therapeutic proteins and other drugs as a stabilizing ingredient. “We found that sugar excipients themselves contain nanometer-sized particles, which can damage proteins and make drugs unsafe,” says Weinbuch. “Potentially, these nanoparticle impurities in sugar could even trigger the immune system themselves — causing unwanted immunogenicity. We are investigating that right now.”

Safe Drug Development

People were not aware of this issue before, according to Weinbuch. He advises new regulatory requirements for safer drug development. “The biopharmaceutical industry needs to be aware of potentially harmful impurities in their excipients, which are added to the drug products. Also the sugar industry has a challenge to produce sugars excipients without these impurities.”

Second Chance for Failed Drugs

Weinbuch’s research is an important step towards the development of safer and more efficient biopharmaceutical drugs. “If a drug fails, it might not be due to the drug substance itself but due to an improper formulation. Using safe formulation excipients potentially gives failed drugs a second chance.”

(Source: AlphaGalileo)


Filed Under: Drug Discovery

 

Related Articles Read More >

The FDA’s AI ambitions depend on better data practices
Researchers working in the clinical laboratory
Outpatient clinics are becoming critical Infrastructure for drug trials
SAS launches clinical trial analytics software built on its Viya cloud native analytics platform
Bayer’s Lynkuet approved by FDA for menopausal hot flashes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE